{"id":"W2511120040","doi":"10.1016/s0140-6736(16)31322-8","title":"Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1379,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Vancouver General Hospital","funders":"Wake Forest School of Medicine; Teva Pharmaceutical Industries; AstraZeneca","keywords":"Benralizumab; Medicine; Placebo; Mepolizumab; Asthma; Exacerbation; Internal medicine; Clinical endpoint; Eosinophil; Gastroenterology; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001913339,0.001828973,0.004011387,0.0005010336,0.0004654045,0.001186147,0.001191981,0.002739331,0.005979724],"category_scores_gemma":[0.001827924,0.0007522667,0.00294451,0.0003769152,0.00130598,0.001048833,0.0004251362,0.003955975,0.001086292],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007476513,"about_ca_system_score_gemma":0.0007968909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001434529,"about_ca_topic_score_gemma":0.003119629,"domain_scores_codex":[0.9994074,0.0002821953,0.00003785361,0.0001058665,0.00005336163,0.0001132267],"domain_scores_gemma":[0.9991035,0.0003346795,0.000164919,0.00005450098,0.00005695423,0.0002853668],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9850792,0.002108644,0.0003021006,0.0009592456,0.001000957,0.00003846758,0.0000343485,0.0001382868,0.001560152,0.00007156876,0.0007167952,0.007990194],"study_design_scores_gemma":[0.9849915,0.01362316,0.0005832055,0.00002367196,0.0002836817,0.00001677337,0.00001048702,0.00008174949,0.00008909499,0.00004220603,0.0002483599,0.000006125327],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.959199,0.02660272,0.0008748631,0.001806255,0.002214796,0.003485889,0.001765468,0.0002599966,0.003791124],"genre_scores_gemma":[0.9754985,0.01003715,0.001435271,0.00277496,0.001170915,0.002799718,0.001577222,0.00004150587,0.004664762],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005979724,"threshold_uncertainty_score":0.02000415,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03361947395121312,"score_gpt":0.3351761485025026,"score_spread":0.3015566745512895,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}